Pulmonary Embolism and &lt;i&gt;L&lt;/i&gt;-Asparaginase Therapy

Guarnaccia, C.; Fanfani, Francesco; Mancuso, Luigi

doi:10.1159/000206589

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Venous thrombosis has been reported in patients with solid tumors and hematological malignancies treated with pegaspargase and L-ASP (11,18). Associations between anti-thrombin III deficiency and venous thromboembolism in patients treated with L-ASP have been reported (19,20).…”

Section: Grade (No Of Patients) ------------------------------------mentioning

confidence: 99%

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety

Hays

Kim

Walker

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The anti-angiogenic activity of L-asparaginase (L-ASP) and the sensitivity of ovarian cancer cell lines to L-ASP has been previously demonstrated by preclinical findings. The aim of this clinical trial was to translate those findings and evaluate the activity of polyethylene glycol-conjugated L-asparaginase (PEG-ASP or pegaspargase) in advanced ovarian cancer. Women with recurrent ovarian cancer and good end-organ function were enrolled in an open-label phase II trial of PEG-ASP at a dose of 2,000 IU/m 2 by intravenous infusion every 2 weeks. Patients were evaluated for response every 8 weeks and for toxicity on an ongoing basis. Early stopping rules for toxicity and activity were included. Four patients were enrolled and received a total of 7 treatment cycles. The study ended accrual by invoking an early stopping rule, after excessive toxicity was identified in patients. Drug-related toxicities included grade 2 pancreatitis, fatigue, neutropenia, hypoalbuminemia, weight loss, dehydration, decreased fibrinogen and 1 case of grade 3 hypersensitivity reaction during cycle 2. One patient died during the study. No patients were evaluable for response. PEG-ASP was poorly tolerated in this group of advanced-stage ovarian cancer patients and no conclusions regarding activity may be drawn. Further studies of PEG-ASP in ovarian cancer patients are not recommended.

show abstract

Section: Grade (No Of Patients) ------------------------------------mentioning

confidence: 99%

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety

Hays

Kim

Walker

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia.

Homans¹,

Rybak²,

Baglini³

et al. 1987

JCO

View full text Add to dashboard Cite

The use of L-asparaginase during remission induction in patients with leukemia is associated with coagulation abnormalities, which may present either as thrombosis or hemorrhage. However, because of the multiple pharmacologic and hematologic variables present in these patients, the exact contribution of L-asparaginase to these coagulation abnormalities is unclear. We studied platelet function and plasma coagulation parameters in 12 pediatric patients with acute lymphoblastic leukemia (ALL) receiving daily L-asparaginase as a single agent when in complete remission. Changes in the prothrombin time (PT), partial thromboplastin time (PTT), and fibrinogen, while statistically significant, remained within or close to the normal range during the study. Platelet function also remained normal during the study. In contrast, levels of protein C antigen decreased to a mean of 42%, a significant change from pretreatment values. Levels of antithrombin III (AT III) were likewise depressed to 15 mg/dL (34% of pretreatment value). Despite these changes in the levels of physiologic inhibitors of coagulation, this schedule of L-asparaginase administration was associated with only rare clinical thrombosis, and this study suggests that the development of this complication may be dependent on the presence of additional factors.

show abstract

Pulmonary Embolism and <i>L</i>-Asparaginase Therapy

Cited by 2 publications

References 4 publications

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety

Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia.

Contact Info

Product

Resources

About